Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note published on Friday. The firm issued a sell rating on the stock.

Separately, Dawson James assumed coverage on Tonix Pharmaceuticals in a report on Wednesday, February 28th. They issued a buy rating and a $3.00 price target for the company.

Tonix Pharmaceuticals Stock Up 1.9 %

TNXP opened at $0.16 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. The stock has a market capitalization of $13.52 million, a price-to-earnings ratio of -0.02 and a beta of 2.21. The business has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.39. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $3.31.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.86) EPS for the quarter. The business had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million. On average, research analysts expect that Tonix Pharmaceuticals will post -3.71 earnings per share for the current year.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Tonix Pharmaceuticals by 1.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,222,424 shares of the company’s stock worth $723,000 after purchasing an additional 14,200 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Tonix Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 371,852 shares of the company’s stock worth $144,000 after acquiring an additional 27,892 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Tonix Pharmaceuticals by 183.9% in the first quarter. Two Sigma Investments LP now owns 60,191 shares of the company’s stock worth $36,000 after acquiring an additional 38,991 shares in the last quarter. Virtu Financial LLC boosted its holdings in shares of Tonix Pharmaceuticals by 44.8% during the fourth quarter. Virtu Financial LLC now owns 188,075 shares of the company’s stock worth $73,000 after purchasing an additional 58,184 shares during the period. Finally, UBS Group AG boosted its holdings in shares of Tonix Pharmaceuticals by 18,868.5% during the fourth quarter. UBS Group AG now owns 67,528 shares of the company’s stock worth $26,000 after purchasing an additional 67,172 shares during the period. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.